Elevated Serum Levels of Soluble CD30 in Ankylosing Spondylitis Patients and Its Association with Disease Severity-Related Parameters.
Elevated Serum Levels of Soluble CD30 in Ankylosing Spondylitis Patients and Its Association with Disease Severity-Related Parameters.
复制标题
DOI：
10.1155/2015/617282
复制
发表时间：
2015
影响因子：
--
通讯作者：
Dong L
中科院分区：
文献类型：
--
作者：
Gao R;Sun W;Chen Y;Su Y;Wang C;Dong L
可溶性CD30(SCD30)是肿瘤坏死因子受体(TNFR)超家族的一种跨膜糖蛋白，与多种病理状态有关。本研究旨在检测强直性脊柱炎(AS)患者血清sCD30水平，并探讨血清sCD30水平与强直性脊柱炎疾病活动指数(BASDAI)、强直性脊柱炎疾病活动评分(ASDAS)、BASFI等疾病严重程度相关指标之间的关系。结果显示，AS患者外周血中sCD30水平显著高于健康对照组，分别为32.0±12.2和2 4.9±8.0 ng/m L(P**=0.007)，提示sCD30在AS的发病机制中可能起重要作用。然而，在我们的研究中，没有发现sCD30与BASDAI、ASDAS或BASFI显著相关(P&gT；0.05)。因此，sCD30不能作为反映AS患者疾病活动性和功能状态的可靠指标。
Soluble CD30 (sCD30), a transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily, has been shown to be associated with various pathological conditions. This study was designed to measure the levels of serum sCD30 in patients with ankylosing spondylitis (AS) and to evaluate the relationships between serum sCD30 levels and other disease severity-related indexes, including bath ankylosing spondylitis disease activity index (BASDAI), ankylosing spondylitis disease activity score (ASDAS), and bath ankylosing spondylitis functional index (BASFI). Our results demonstrated significantly elevated sCD30 levels in AS patients compared to healthy controls (HCs) with mean values of 32.0 ± 12.2 and 24.9 ± 8.0 ng/mL, respectively (P ** = 0.007), suggesting a potential role of sCD30 in the pathogenesis of AS. However, no significant correlations of sCD30 with BASDAI, ASDAS, or BASFI were detected in our study (P > 0.05). Therefore, sCD30 cannot be used as a reliable marker for reflecting disease activity and functional ability of AS patients.